The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
Malignant Pleural Mesothelioma (MPM) remains a relevant public health issue, and asbestos exposure is the most relevant risk factor. The incidence has considerably and constantly increased over the past two decades in the industrialized countries and is expected to peak in 2020-2025. In Italy, a standardized-rate incidence in 2011 among men was 3.5 and 1.25 per 100,000 in men and women, respectively, and wide differences are noted among different geographic areas. The disease remains challenging in terms of diagnosis, staging and treatment and an optimal strategy has not yet been clearly defined. The Third Italian Multidisciplinary Consensus Conference on Malignant Pleural Mesothelioma was held in Bari (Italy) in January 30-31, 2015. This Consensus has provided updated recommendations on the MPM management for health institutions, clinicians and patients.
Department of Oncology, University of Turin, Italy. Electronic address: silvia.novello@unito.it.
S
S
Novello
Medical Oncology Unit, IRCCS-Arciospedale Santa Maria Nuova, Reggio Emilia, Italy.
C
C
Pinto
Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
V
V
Torri
Department of Oncology, IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
L
L
Porcu
Department of Oncology, University of Turin, Italy.
M
M
Di Maio
Division of Medical Oncology, Azienda Ospedaliera Universitaria di Parma, Italy.
M
M
Tiseo
Thoracic Oncology Unit, Humanitas Gavazzeni, Bergamo, Italy.
G
G
Ceresoli
Cancer Epidemiology, University of Eastern Piedmont and CPO-Piemonte, Novara, Italy.
C
C
Magnani
Istituto per lo Studio e la Prevenzione Oncologica, Florence, Italy.
S
S
Silvestri
Department of Oncology, University of Turin, Italy.
A
A
Veltri
Department of Oncology, University of Turin, Italy.
M
M
Papotti
Ospedale Policlinico, Division of Human Pathology, Modena, Italy.
G
G
Rossi
Department of Oncology, University of Turin, Italy.
U
U
Ricardi
Department of Radiotherapy, Campus Bio-Medico University, Rome, Italy.
L
L
Trodella
Azienda Ospedaliera, Division of Thoracic Surgery, Padua, Italy.
F
F
Rea
Regina Elena Cancer Institute, Division of Thoracic Surgery, Rome, Italy.
F
F
Facciolo
University of Torino, Department of Psychology, Italy.
A
A
Granieri
Veneto Oncology Institute, IRCCS Padova, Italy.
V
V
Zagonel
Department of Oncology, University of Turin, Italy.
G
G
Scagliotti
D000818:Animals; D006801:Humans; D015994:Incidence; D007558:Italy / Q000453:epidemiology; D008175:Lung Neoplasms / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D008654:Mesothelioma / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D000086002:Mesothelioma, Malignant; D010996:Pleural Effusion / Q000209:etiology; D010997:Pleural Neoplasms / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D011634:Public Health; D012307:Risk Factors
Diagnosis; End of life; Epidemiology; Malignant Pleural Mesothelioma; Recommendations; Supportive care; Therapy